CSS
STML

Cubist Systematic Strategies’s Stemline Therapeutics, Inc. STML Stock Holding History

Cubist Systematic Strategies’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-29,138
Closed -$141K – 2611
2020
Q1 		$141K Buy
29,138
+14,893
+105% +$96.6K ﹤0.01% 1827
2019
Q4 		$151K Sell
14,245
-6,956
-33% -$69.1K ﹤0.01% 2102
2019
Q3 		$221K Buy
+21,201
New +$277K ﹤0.01% 1725
2019
Q2 		– Sell
-6,788
Closed -$87K – 2667
2019
Q1 		$87K Sell
6,788
-14,233
-68% -$161K ﹤0.01% 2025
2018
Q4 		$200K Buy
21,021
+20,752
+7,714% +$269K 0.01% 1545
2018
Q3 		$4K Buy
+269
New +$4.31K ﹤0.01% 1842

Cubist Systematic Strategies's STML Position: Q2 2020 in Review

Cubist Systematic Strategies sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 29,138 shares — an estimated $141K sold.

Cubist Systematic Strategies first reported a position in STML in Q3 2018 and held it in 6 quarters. The position peaked at $221K in Q3 2019. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.

  • Cubist Systematic Strategies reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
  • Cubist Systematic Strategies sold 29,138 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $141K.
  • Cubist Systematic Strategies first reported a position in Stemline Therapeutics, Inc. in Q3 2018 and held it in 6 quarters.
  • Cubist Systematic Strategies's Stemline Therapeutics, Inc. position peaked at $221K in Q3 2019.
  • 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.

Based on Cubist Systematic Strategies's 13F filing for Q2 2020, filed 14 Aug 2020.